Dss Inc Stock Price, News & Analysis

DSS, a multinational company, announced the appointment of two independent directors to its Board: Frankie Wong and Joanne Wong Hiu Pan. Frankie Wong brings over 20 years of experience in financial reporting and has served in CFO roles at various listed companies. Joanne Wong has over 15 years in the financial industry as an investment manager. CEO Frank D. Heuszel stated that their addition enhances the board's expertise in legal, operations, financing, and more, supporting DSS's vision across its nine business divisions.

Impact Biomedical, a subsidiary of DSS, has signed a license agreement with ProPhase Labs for Equivir, a treatment aimed at reducing the occurrence and severity of viral outbreaks. With human clinical trials set to commence soon, Equivir, which has received two U.S. patents, is believed to block viral entry into host cells. The partnership leverages ProPhase's extensive experience in health product distribution, potentially expediting Equivir's market entry. The treatment may combat various viruses, including influenza and SARS-CoV-2, addressing critical global health needs.

DSS, Inc. announced that its subsidiary, Global BioLife, received a patent in China for its innovative mosquito repellant technology, 3F™. This formulation utilizes botanical oils to incapacitate mosquito receptors, enhancing its effectiveness over traditional repellants. The global mosquito repellant market is projected to grow from $6.9 billion in 2021 to $10.9 billion by 2028, with China recognized as a leading market. Frank Heuszel, President of Impact BioMedical, emphasized the technology's potential for licensing and commercialization, which could drive shareholder value.

DSS, Inc. (NYSE American: DSS) announced an upcoming interview with COO Jason Grady on The RedChip Money Report, airing on Bloomberg U.S. on May 7 at 7 p.m. ET. The show provides insights into small cap investing and features executives from public companies. DSS operates nine business divisions, focusing on strategic acquisitions and IPO spinoffs to enhance shareholder value. The company's diversified portfolio aims to drive profitability in high-growth sectors.

Impact Biomedical, a subsidiary of DSS, announced a positive report on its compound Equivir's international patentability for treating viral infections. The Patentability Report from WIPO indicated no prior art blocking patent claims for Equivir, which may limit viral outbreaks. This marks the third positive step for Equivir, following two U.S. patents awarded for its efficacy against influenza, Ebola, and rhinovirus. Equivir operates by blocking viruses from entering host cells and has potential applications against multiple viral infections, including SARS COV2.

DSS, Inc. (NYSE American: DSS) announced a transformative year ahead, supported by a substantial restructuring since late 2019. The firm boasts over $219 million in assets, including $69 million in cash. Aiming for a breakout year, DSS plans to acquire True Partner Capital, enhancing its global securities business. Recent public offerings generated over $121 million, aiding in strategic medical real estate acquisitions with yields around 8%. DSS expresses optimism about significant growth and potential IPOs in 2022, reflecting the company’s diverse portfolio and commitment to shareholder value.

DSS, Inc. (NYSE American: DSS) announces a letter to shareholders highlighting its transformative journey since 2019. The company's assets have surged from $16.2 million to over $219 million, fueled by acquisitions and divestitures. DSS plans an acquisition of True Partner Capital, boosting its securities business with $1.7 billion in assets under management. The company has raised over $121 million through public offerings and is pursuing spinoffs to enhance shareholder value. With strong growth in medical real estate and direct selling, DSS anticipates significant revenue increases in 2022.

DSS, a multinational company with diverse business interests, will present at the Aegis Capital Corp. Virtual Conference on February 25 at 9:30 a.m. EST. The conference is scheduled from February 23 to 25, operating daily from 8:30 a.m. to 5 p.m. EST. Interested parties can access DSS's presentation by requesting it through Aegis during the conference. DSS operates in sectors such as blockchain security, healthcare, and renewable energy, focusing on sustainable growth and value creation through innovative solutions.

DSS, Inc. (NYSE American: DSS) has entered a stock purchase agreement with Alset EHome International, Inc. to issue up to 44,619,423 shares at $0.3810 each, pending shareholder approval. CEO Frank D. Heuszel described this as a strong vote of confidence that will enhance the company's balance sheet, enabling it to pursue growth opportunities across multiple sectors. COO Jason Grady emphasized the efforts to build a foundation for shareholder value creation, gearing up for the next phase of growth focused on top-line and bottom-line performance.